Physician profile
Lawrence Minardi
NPI 1174508774
$6,730.78
in general payments reported to CMS, 2019-2025
29 companies · $1,426 in 2025
The $1,426 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,261 · 2020: $431 · 2021: $840 · 2022: $660 · 2023: $895 · 2024: $1,216 · 2025: $1,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,537.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,179.06 | 2019-2025 | Simbrinza, Clareon Panoptix Pro, Clareon |
| Abbvie INC. | $611.75 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $544.21 | 2022-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $531.65 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $493.15 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Amgen INC. | $409.24 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $382.27 | 2019-2021 | |
| Allergan, INC. | $360.79 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $295.66 | 2019-2021 | |
| Horizon Therapeutics Plc | $212.82 | 2021-2023 | Tepezza |
| Ani Pharmaceuticals, INC. | $206.80 | 2025 | Purified Cortrophin Gel |
| Tarsus Pharmaceuticals, INC. | $199.68 | 2025 | Xdemvy |
| Dompe US, INC. | $177.47 | 2019-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $160.78 | 2019-2021 | |
| Glaukos Corporation | $151.57 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $149.64 | 2021 | |
| Biotissue Holdings INC. | $120.48 | 2019-2025 | |
| Rxsight INC | $89.93 | 2022 | |
| Oyster Point Pharma, INC. | $88.94 | 2022-2024 | Tyrvaya |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Thea Pharma INC. | $58.93 | 2024-2025 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $57.73 | 2021 | |
| Harrow Eye, LLC | $45.65 | 2024 | Vevye, Iheezo |
| Eyevance Pharmaceuticals LLC | $39.40 | 2022 | |
| Shire North American Group INC | $38.41 | 2019 | |
| Omeros Corporation | $20.26 | 2020 | |
| Lkc Technologies, INC. | $17.54 | 2025 | |
| Sight Sciences, INC. | $13.52 | 2024 | Omni Surgical System |
| New World Medical,INC. | $8.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Minardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.